| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL1350 | Name | TP53TG1 | Aliases | LINC00096; NCRNA00096; P53TG1; P53TG1-D; TP53AP1 | |
| Species | Homo sapiens | Chromosome | 7 | Start site | 87325225 | |
| End site | 87345515 | Chain | minus | Exon NO. | 3 | |
| Assembly | Ensembl Release 89 | Class | lincRNA | NCBI accession | NR_015381 | |
| Ensembl | ENSG00000182165 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| non-small cell lung cancer | microarray, qPCR, Western bolt, knockdown etc. | cell lines (A549, CDDP etc.) | down-regulated | N/A | For lncRNA, the results showed that AK123263, CES1P1-001, RP3-508I15.14, AK126698, TP53TG1, and AC090952.4.1 decreased, whereas uc003bgl.1 and NCRNA00210 increased in A549/CDDP (all P <0.05). Cisplatin resistance in non-small-cell lung cancer cells may relate to the changes in noncoding RNAs. Among these, AK126698 appears to confer cisplatin resistance by targeting the Wnt pathway. | 23741487 | Lnc2Cancer | ||
| ataxia telangiectasia | N/A | human T lymphocytes from patient with ataxia telangiectasia (AT) | up-regulated | expression | TP53TG1 demonstrated a weak up-regulation, reaching a maximum of 1.5-fold at 24 h after radiation exposure | 25738893 | |||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| TP53 | DNA-TF | regulation | TP53 target gene 1 | 9713990 | LncRNADisease | ||||